HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...

Study findings suggest that the ratio of interleukin-10 to tumor necrosis factor-alpha produced by transitional-1 B cells can predict renal allograft outcomes with a lead time of about 8 months.